A Review of the Treatment of Psoriasis with Infliximab

Author(s): Theodora Vamvouris, Suhail Hadi.

Journal Name: Reviews on Recent Clinical Trials

Volume 1 , Issue 3 , 2006

Become EABM
Become Reviewer

Abstract:

Patients afflicted with moderate to severe psoriasis experience a reduction in the quality of life. They not only suffer the aggravation associated with the pain, itchiness, and bleeding of the psoriatic lesions, but also experience a negative impact on their daily functions and social well-being. Unfortunately, traditional therapeutic measures have not been effective enough in treating individuals suffering from moderate to severe forms of psoriasis. Most of the conventional medications have produced at best only partial responses. However, the recent chimeric monoclonal TNF-α inhibiting antibody, infliximab, has been proven effective for the treatment of patients with moderate to severe psoriasis. Most patients treated with infliximab have shown rapid and remarkable improvement in the clinical manifestations of the disease. This article will closely examine the efficacy and safety of infliximab through the analysis of past case reports and clinical trials.

Keywords: tumor necrosis factor alpha, inflammatory response, Psoriasis Area and Severity Index (PASI), Aminotransferase, infliximab

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 1
ISSUE: 3
Year: 2006
Page: [201 - 205]
Pages: 5
DOI: 10.2174/157488706778250122
Price: $58

Article Metrics

PDF: 5